181 related articles for article (PubMed ID: 38141254)
1. Whole tumor analysis reveals early origin of the TERT promoter mutation and intercellular heterogeneity in TERT expression.
Appin CL; Hong C; Suwala AK; Hilz S; Mathur R; Solomon DA; Smirnov IV; Stevers NO; Shai A; Wang A; Berger MS; Chang SM; Phillips JJ; Costello JF
Neuro Oncol; 2024 Apr; 26(4):640-652. PubMed ID: 38141254
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
3. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas.
Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K
Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
[No Abstract] [Full Text] [Related]
5. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
6. Sensitive and rapid detection of TERT promoter and IDH mutations in diffuse gliomas.
Diplas BH; Liu H; Yang R; Hansen LJ; Zachem AL; Zhao F; Bigner DD; McLendon RE; Jiao Y; He Y; Waitkus MS; Yan H
Neuro Oncol; 2019 Mar; 21(4):440-450. PubMed ID: 30346624
[TBL] [Abstract][Full Text] [Related]
7. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
[TBL] [Abstract][Full Text] [Related]
8. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
Pekmezci M; Rice T; Molinaro AM; Walsh KM; Decker PA; Hansen H; Sicotte H; Kollmeyer TM; McCoy LS; Sarkar G; Perry A; Giannini C; Tihan T; Berger MS; Wiemels JL; Bracci PM; Eckel-Passow JE; Lachance DH; Clarke J; Taylor JW; Luks T; Wiencke JK; Jenkins RB; Wrensch MR
Acta Neuropathol; 2017 Jun; 133(6):1001-1016. PubMed ID: 28255664
[TBL] [Abstract][Full Text] [Related]
9. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas.
Liu EM; Shi ZF; Li KK; Malta TM; Chung NY; Chen H; Chan JY; Poon MF; Kwan JS; Chan DT; Noushmehr H; Mao Y; Ng HK
Brain Pathol; 2022 Nov; 32(6):e13107. PubMed ID: 35815721
[TBL] [Abstract][Full Text] [Related]
10. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
11. Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody.
Masui K; Komori T; Kato Y; Masutomi K; Ichimura K; Ogasawara S; Kaneko MK; Oki H; Suzuki H; Nitta M; Maruyama T; Muragaki Y; Kawamata T; Sawada T; Shibata N
Biomed Res Int; 2018; 2018():7945845. PubMed ID: 29693015
[TBL] [Abstract][Full Text] [Related]
12. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Arita H; Yamasaki K; Matsushita Y; Nakamura T; Shimokawa A; Takami H; Tanaka S; Mukasa A; Shirahata M; Shimizu S; Suzuki K; Saito K; Kobayashi K; Higuchi F; Uzuka T; Otani R; Tamura K; Sumita K; Ohno M; Miyakita Y; Kagawa N; Hashimoto N; Hatae R; Yoshimoto K; Shinojima N; Nakamura H; Kanemura Y; Okita Y; Kinoshita M; Ishibashi K; Shofuda T; Kodama Y; Mori K; Tomogane Y; Fukai J; Fujita K; Terakawa Y; Tsuyuguchi N; Moriuchi S; Nonaka M; Suzuki H; Shibuya M; Maehara T; Saito N; Nagane M; Kawahara N; Ueki K; Yoshimine T; Miyaoka E; Nishikawa R; Komori T; Narita Y; Ichimura K
Acta Neuropathol Commun; 2016 Aug; 4(1):79. PubMed ID: 27503138
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases.
Na K; Kim HS; Shim HS; Chang JH; Kang SG; Kim SH
J Neurooncol; 2019 May; 142(3):445-454. PubMed ID: 30710203
[TBL] [Abstract][Full Text] [Related]
15. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
16. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.
Terzi NK; Yilmaz I; Oz AB
Turk Patoloji Derg; 2022; 38(2):90-98. PubMed ID: 34558656
[TBL] [Abstract][Full Text] [Related]
17.
Juratli TA; Stasik S; Zolal A; Schuster C; Richter S; Daubner D; Juratli MA; Thowe R; Hennig S; Makina M; Meinhardt M; Lautenschlaeger T; Schackert G; Krex D; Thiede C
Clin Cancer Res; 2018 Nov; 24(21):5282-5291. PubMed ID: 29941484
[No Abstract] [Full Text] [Related]
18. Glioblastomas harboring gene fusions detected by next-generation sequencing.
Woo HY; Na K; Yoo J; Chang JH; Park YN; Shim HS; Kim SH
Brain Tumor Pathol; 2020 Oct; 37(4):136-144. PubMed ID: 32761533
[TBL] [Abstract][Full Text] [Related]
19. Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas.
Hong L; Shi ZF; Li KK; Wang WW; Yang RR; Kwan JS; Chen H; Li FC; Liu XZ; Chan DT; Li WC; Zhang ZY; Mao Y; Ng HK
Lab Invest; 2022 Jul; 102(7):731-740. PubMed ID: 35332262
[TBL] [Abstract][Full Text] [Related]
20. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
